cyrilzakka/clinical-trials huggingface dataset:
Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia

Background: Non-specific neck pain (NS-NP) is characterized by pain in structures located in the region between the superior nuchal line and the spinal process of the first thoracic vertebra, without association with any specific systemic disease provided by multifactorial and/or little known causes.

Objective: The objective of the present study will be to verify the clinical effects of MV through visceral nociceptive inhibition in NS-NP patients with functional dyspepsia.

Methods: In this study sixty NS-NP patients with functional dyspepsia (age: 18 and 50 years) will be randomized in into two groups: visceral manipulation group (VMG) (n =30) and control group (CG) (n =30). The VMG will be treated with visceral manipulation to the stomach and liver wile CG received placebo treatment. The immediate effects and 7 days after treatment will be evaluated through pain, cervical range, and electromyographic activity of the upper trapezius.


Eligibility Criteria:
Inclusion Criteria:

* history of neck pain for a minimal period of the three months;
* neck with restricted movement (active or passive) in at least one direction;
* Neck Disability Index considering score range of 11-24 (score out of a 50) ;
* numerical rating scale (NRS) for perceived pain intensity considering 3-7 points on an 11-point;
* Presence of symptoms related to functional dyspepsia, according to the Rome III diagnostic criteria: uncomfortable postprandial fullness, early satiety, epigastric pain and epigastric burning, accompanied by no evidence of structural disease capable of explaining the symptoms .

Exclusion Criteria:

* Individuals with history of neurological disorders (i.e., irradiated pain) or neck surgery; systemic disease; connective tissue disorder and herniated disc;
* current pregnancy;
* medical diagnosis of fibromyalgia;
* physical therapy treatment with, massage, or acupuncture in the previous two weeks;
* use of analgesic, muscle relaxant, psychotropic agent, or anti-inflammatory agent in the previous three days;
* chronic neck pain resulting from a traumatic incident; chronic musculoskeletal condition (e.g., muscular disorder, polyarthritis).
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.

A randomised, open-label, parallel group study to evaluate the management of rosiglitazone-related fluid retention by investigating the effect of diuretics on plasma volume in subjects with type 2 diabetes mellitus treated for twelve weeks with rosiglitazone 4mg bd in addition to background anti-diabetic agents.

Eligibility Criteria:
Inclusion criteria:

* Subjects with type 2 diabetes.
* Stable FPG of \>=7.0 and \<=12.0mmol/L.
* Subjects had to have been established on SU treatment or SU+MET treatment for at least 2 months.
* Serum creatinine level \> 130 micromol/L.

Exclusion criteria:

* Subjects taking \> 2 concomitant oral anti-diabetic agents.
* Subjects with HbA1c \>=10%.
* Subjects already receiving diuretic medication.
* Subjects unstable or severe angina.
* CHF NYHA class i-iv.
* Subjects with clinically significant hepatic disease.
Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation

The primary objective is to characterize the programming effects of Boston Scientific Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of Parkinson's disease in acute and chronic settings.


Eligibility Criteria:
Key Inclusion Criteria:

* Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one (1) of the following: resting tremor or bradykinesia.
* UPDRS III score of \>25 in the meds OFF condition
* Medication must improve PD symptoms by ≥30%, as measured by UPDRS subset III score

Key Exclusion Criteria:

* Any significant psychiatric problems, including unrelated clinically significant depression as determined by the investigator
* Any current drug or alcohol abuse as determined by the investigator
* Any history of recurrent or unprovoked seizures
* Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival \<12 months
Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus

To compare patients and nurses using insulin pen injector to inject premixed insulin respectively, using continuous glucose monitoring system to evaluate the glucose excursion in the two sets, study the relationship between glucose excursion and inject technique in type 2 diabetes mellitus.

A total of 60 patients with type 2 diabetes who used premixed insulin will enrolled in this study.Measure their blood pressure，height and weight, BMI, liver and kidney function, blood lipids, glycosylated hemoglobin, fasting glucose, 2 hour postprandial glucose，fasting C peptide, 2 hour postprandial C peptide, fasting glucagon, 2 hour postprandial glucagon,fasting serum insulin，2 hour postprandial serum insulin，urinary albumin and insulin antibodies.The first and second days，the patients inject premixed insulin themselves，the specialist nurse graded the patient's injection technique score.The third and the fourth days the nurse change a new insulin with the same types maintain the same injection dosage.The patient need perform continuous glucose monitoring system(CGMS) for 96-hours.

Eligibility Criteria:
Inclusion Criteria:

1. type 2 diabetes patients
2. aged 20-80 years
3. had been on premixed insulin and used an insulin pen for at least 3 months
4. fasting glucose between 6.1-16 mmolL, postprandial(or random) glucose below 22.2mmol/L.
5. No acute complications such as diabetic ketoacidosis, diabetic hypertosmolar syndrome.
6. Subjects were able and willing to ues CGMS and eat regularly.
7. Patients who were able to inject insulin themselves or actual injections can be accompanied.

Exclusion Criteria:

1. Insulin allergy.
2. There has been a history of drug abuse and alcohol dependence in the past five years, or systemic hormone therapy within 3 months.
3. Patients with poor compliance and irregular eating and exercise.
4. Infection or stress within four weeks.
5. Patients unable to tolerate CGMS.
6. patients with pregnancy, breast-feeding, planning to have a baby
7. patients with coagulopathy, serious complication,such as cardiovascular disease, end stage renal disease; and patients with severe retinopathy or other eye problems that impair their visual function, or cognitive dysfunction
Interest of Cardiac Coherence in the Prevention of Chronic Post-traumatic Stress Disorder: Pilot Study

ThThe aim of this study is to determinate the potential benefits of a respiratory training program (cardiac coherence, CC) in patients suffering from acute stress disorder, after a potentially traumatic event. Using this method is supposed to prevent the onset of chronic post traumatic stress disorder after 3 months.

This pilot study will help to determinate the need of developing this kind of complementary and alternative program, and will also provide knowledge about the feasibiility and acceptability of this program for the patients.

Each patient will be teached how to use cardiac coherence with a trained practitioner at the inclusion visit. A respiratory guide on smartphone will be given to the patient aswell as a diary in order to keep tracks of the patient's compliance to this program.

Eligibility Criteria:
Inclusion Criteria:

* patients seen at medico-psychological emergency cell
* patients with an acute stress disorder, diagnosed by DSM-5
* patients who have experienced a potentially traumatic event for the last 3-15 days (vctim or witness)
* patients able to read and write in French language
* person affiliated or beneficiary of a social security scheme.
* person who agrees to participate in the study

Exclusion Criteria:

* patients with respiratory pathology not allowing cardiac coherence training
* patients currently practicing a regular respiratory control technique or within the last 6 months
* patients taking beta-blocker, betamimetic, anti-arrhythmic, opioid, antidepressant
* patients with a pacemaker or suffering from severe cardiac illness
* patients with non-stabilized psychiatric disorder at inclusion
* patient taking benzodiazepine unable to wean off in the week following the inclusion
* patients with addiction
* patients with a cognitive deficit
* patients under guardianship or curatorship, under judicial supervision
Evaluating the Efficacy of the Parent Support Program

The objective of the study is to evaluate the efficacy of an online intervention (the Parents Support Program) aimed at increasing supportive behaviors among parents of transgender youth. The intervention consists of three modules that include a variety engaging activities such as social perspective taking exercises, writing prompts, videos of parents, youth, and experts, and psycho-educational materials. The study uses an experimental design with a waitlist control. Both the experimental and control groups will complete a pre-test, one month follow up, and two month follow up survey. Targeted outcomes include knowledge about gender diversity, attitudes about trans youth, and supportive parenting behaviors.


Eligibility Criteria:
Inclusion Criteria:

* Must be 18 years of age or older.
* Must live in the United States.
* Must be comfortable communicating in English.
* Must be a parent of a trans child between the ages of 10 - 24.

Exclusion Criteria:

* Participants who participated in pilot study or focus groups related to this project.
Uremic Toxins of Patients With Acute Kidney Failure

Determination of the concentration of uremic toxins of sepsis patients with or without acute kidney failure compared to the concentrations of uremic toxins of chronically uremic patients

Determination of the concentration of uremic toxins of sepsis patients with or without acute kidney failure compared to the concentrations of uremic toxins of chronically uremic patients

Eligibility Criteria:
Inclusion Criteria:

* Intensive Care patients with sepsis
* Patients with acute kidney failure: serum creatinin \> 2 mg/dl
* Chronic haemodialysis patients

Exclusion Criteria:

* \< 18 years
FAMily Oriented Support (FAMOS): Psychosocial Intervention for Childhood Cancer Survivors and Their Families

To investigate whether a home-based psychosocial family intervention that takes place shortly after ending the primary medical treatment can help families adjust to their cancer-related psychological issues.

The objective of this randomized controlled trial is to investigate whether home-based psychosocial interventions are able to help families of childhood cancer survivors cope with cancer-related psychological issues.

Method: 300 families will be recruited from the four pediatric oncology departments in Denmark where 150 families' will receive a home-based psychosocial intervention and 150 families will be in the control group. The study will take place shortly after the child completes the primary treatment. The primary outcome is post-traumatic stress symptoms (PTSS) in parents and secondary outcomes include among others quality of life, sick-leave, coping strategies and family functioning. Families in the intervention group will receive a 6 session manualized intervention based on a Cognitive Behavioral framework. Four sessions will focus on the parents and two sessions will focus on the child, who had cancer, and his/her siblings. The main goal of the sessions is to teach families how to adapt healthy psychological adjustments to pediatric oncology and prevent PTSS in family members. As a part of the intervention, families will be presented with video clips of other parents discussing how cancer has affected their family, to show common issues in experiencing having a child undergo cancer treatment. Every family member will be asked to complete a set of questionnaires to measure the outcome of the intervention at baseline before the intervention, 6 months follow-up and 12 months follow-up.

It is expected that families in the intervention group experience a larger improvement in their post-traumatic stress symptoms as well as strengthening the family function, quality of life and reducing sick leave compared to the control group.

Eligibility Criteria:
Inclusion Criteria:

* Families of children in the age range of 0-17 years diagnosed with any kind of cancer and treated at one of the four pediatric oncology departments in Denmark are invited to participate in the project after ending primary medical treatment.

Exclusion Criteria:

* If the child has a severe co-morbidity
* If the child has a mental disorder at diagnosis
* If the child is declared terminal ill at the end of treatment (less than 6 months of survival).
* If the parents and the children do not speak Danish. The participants have to be able to read and answer the questionnaires at the least, to be included in the project.
* If the parents do not wish to hand in consent form
* If the family participates in another randomized psychosocial intervention project
Treatment of Postpartum Urinary Retention

The aim of the study is to evaluate what is the most effective catheterization duration to resolve covert and overt postpartum urinary retention following vaginal delivery and caesarean delivery, with the highest patients' satisfaction.

1. Women who are unable to micturate for more than 6-8 hours following vaginal delivery or within six to eight hours following removal of an indwelling catheter after cesarean delivery (overt postpartum urinary retention), or women with postvoid residual bladder volume of at least 150 mL (covert postpartum urinary retention) will be randomized into 2 groups: one group will include women who are catheterized intermittently every 6-8 hours up to a total time of 48 hours. If at any time, post voiding residual volume is less than 150cc (assessed by ultrasound or by catheterization), no additional catheterization is needed. The second group will include women which will have an indwelling catheter inserted for 24 hours. The catheter will be removed 24 hours following its insertion and post voiding residual volume will be assessed 6 hours following the catheter removal (by ultrasound or by catheterization). In cases of post voiding residual volume more than 150 cc or women are unable to micturate spontaneously, an indwelling catheter will be inserted for additional 24 hours.
2. After 48 hours from postpartum urinary retention diagnosis, an indwelling catheter will be inserted for additional time that will be set at every center by its common protocol.

Eligibility Criteria:
Inclusion Criteria:

* Women who deliver at one of the centers included in the study
* Overt postpartum urinary retention which refers to the absence of spontaneous micturition within six to eight hours of vaginal delivery; or within six to eight hours following removal of an indwelling catheter after cesarean delivery
* Covert postpartum urinary retention diagnosed by ultrasound or catheterization of more than 150cc

Exclusion Criteria:

* Spontaneous micturition 6-8 hours following vaginal or cesarean delivery
* postpartum urinary retention less than 150cc on ultrasound
* Known urinary tract infection
Ultrafine Particles and Fetal Contamination

The objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

Epidemiological studies have demonstrated the harmful effects of particulate air pollution on the progress of pregnancy and postnatal health.

Experimental studies have suggested the transplacental passage of asbestos fibers, but despite the strong growth in the use and production of fine and ultrafine particles, no study has examined the permeability of the placenta to these compounds or the exposures fetuses that may result.

The objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

Eligibility Criteria:
Inclusion Criteria:

- All women volunteers for whom a medical termination of pregnancy is proposed for a fetus older than 22 weeks (weight over 500g).

Exclusion Criteria:

* Refusal of participation of the patient.
* Fetus with malformation syndrome affecting pulmonary perfusion.
Meta-analysis of Stannous Fluoride and the Effects on Dental Plaque

The aim of this 18 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) dentifrices when used up to 3 months on dental plaque relative to a positive or negative control dentifrice.


Eligibility Criteria:
Subjects were excluded from this study for the following reasons;

* pregnancy,
* rampant caries,
* severe periodontitis,
* at discretionary of the Principal Investigator.
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.


Eligibility Criteria:
Inclusion Criteria:

* Be willing and able to comply with study visits and procedures;
* Have signed written informed consent prior to participating in this extension study;
* Have completed either antecedent study AG348-C-006 or AG348-C-007 through the Part 2 Week 24 Visit;
* Cohorts 2 and 3: Have demonstrated clinical benefit from AG-348 treatment in the antecedent study, in the opinion of the Investigator;
* For women of reproductive potential, have a negative pregnancy test during screening;
* For women of reproductive potential as well as men with partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study drug for women and 90 days following the last dose of study drug for men.

Exclusion Criteria:

* Have a significant medical condition (including clinically significant laboratory abnormality) that developed during his/her antecedent AG- 348 study that confers an unacceptable risk to participating in this extension study, that could confound the interpretation of the study data, and/or that compromises the ability of the participant to complete study visits and procedures.
* Are currently pregnant or breastfeeding.
* Have a splenectomy scheduled during the study treatment period.
* Meet the withdrawal criteria of his/her antecedent AG-348 study during screening of this extension study.
* Are currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4 that have not been stopped for a duration of at least 5 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug; or strong inducers of CYP3A4 that have not been stopped for a duration of at least 28 days or a time frame equivalent to 5 half-lives (whichever is longer) before start of study drug on this extension study.
* Have received anabolic steroids, including testosterone preparations, within 28 days prior to start of study drug on this extension study.
* Have received hematopoietic stimulating agents (eg, erythropoietins, granulocyte colony stimulating factors, thrombopoietins) within 28 days prior to start of study drug on this extension study.
* Have exposure to any investigational drug other than AG-348, device, or procedure within 3 months prior to start of study drug on this extension study.
Built-in Calculator Optimizes Continuous Veno-venous Hemofiltration Prescription and Improves Therapeutic Quality in Critically-ill Acute Kidney Injury Patients

The goal of this observational study is to compare in ICU patients received CVVH treatment. The main questions it aims to answer are:

Control of Filtration fraction by built-in calculator

* Reduced filter clotting and prolong filter lifespan
* Improve patient mortality Participants will divided into before group and after group based on the day when built-in calculator for calculating Filtration fraction was utilized.

Researchers will compare before group to see if there were differences in clotting events, filter downtime, filter lifespan, mortality, etc.

# built-in calculator for calculating Filtration fraction

* The calculator was built in prescription system since 2020/10/01
* providing tempt filtration fraction for operators to adjust CVVH dose
* the protocol of patient care didn't change between before and after group.

Eligibility Criteria:
Inclusion Criteria:

* ICU patients received CVVH during 2019\~2021 (3 years) in our hospital

Exclusion Criteria:

* under age of 20, pregnant, or with HIV infection
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be recorded.

Hepatic carcinoma is the fifth most common cancer worldwide and a large proportion of patients are unsuitable for tumor resection because of factors such as poor hepatic reserve(cirrhosis) which directly lead a poor liver function. Direct ablative treatments include radiofrequency ablation, microwave (MW) ablation and cryotherapy and irreversible electroporation had been used successful as a therapeutic choice for unresectable patients. At the same time，Irreversible electroporation(IRE)，which was applied with a novel ablation technology, can induce tissue necross by utilizing short pulses of high-voltage electrical energy. The technique also had many advantages, including Short ablation time, preservation of vital structures within IRE-ablated zone, avoidance of heat/cold-sink effect, complete ablation with well-demarcated margin and real-time monitoring of IRE ablation.

Eligibility Criteria:
Inclusion Criteria:

* Hepatic carcinoma diagnosed by positive biopsy or non-invasive criteria,
* not suitable for surgical resection or transplantation,
* have at least one, but less than or equal to 3 tumors,
* of the tumour(s) identified, each tumor must be ≤ 5 cm in diameter,
* Child-Pugh class B or ≤12，
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* American Society of Anaesthesiologists (ASA) score ≤ 3,
* a prothrombin time ratio \> 50%,
* platelet count \> 80x109/L,
* ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* are able to comprehend and willing to sign the written informed consent form (ICF),
* have a life expectancy of at least 3 months.

Exclusion Criteria:

* eligible for surgical treatment or transplantation for HCC,
* Hepatic carcinoma developed on an already transplanted liver,
* cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* any active implanted device (eg Pacemaker),
* women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System, are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.